These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
582 related articles for article (PubMed ID: 25776529)
21. Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer. Chen X; Liu Y; Zhang L; Chen D; Dong Z; Zhao C; Liu Z; Xia Q; Wu J; Chen Y; Zheng X; Cai Y Eur J Med Chem; 2021 Mar; 214():113219. PubMed ID: 33618175 [TBL] [Abstract][Full Text] [Related]
22. Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling. Shigesawa T; Maehara O; Suda G; Natsuizaka M; Kimura M; Shimazaki T; Yamamoto K; Yamada R; Kitagataya T; Nakamura A; Suzuki K; Ohara M; Kawagishi N; Umemura M; Nakai M; Sho T; Morikawa K; Ogawa K; Ohnishi S; Sugiyama M; Mizokami M; Takeda H; Sakamoto N Carcinogenesis; 2021 Feb; 42(1):58-69. PubMed ID: 32449510 [TBL] [Abstract][Full Text] [Related]
23. Interrupting the FGF19-FGFR4 Axis to Therapeutically Disrupt Cancer Progression. Lang L; Shull AY; Teng Y Curr Cancer Drug Targets; 2019; 19(1):17-25. PubMed ID: 29557750 [TBL] [Abstract][Full Text] [Related]
24. Up-regulation of FGF15/19 signaling promotes hepatocellular carcinoma in the background of fatty liver. Cui G; Martin RC; Jin H; Liu X; Pandit H; Zhao H; Cai L; Zhang P; Li W; Li Y J Exp Clin Cancer Res; 2018 Jul; 37(1):136. PubMed ID: 29973237 [TBL] [Abstract][Full Text] [Related]
25. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation. Zhao H; Lv F; Liang G; Huang X; Wu G; Zhang W; Yu L; Shi L; Teng Y Oncotarget; 2016 Mar; 7(12):13575-86. PubMed ID: 26498355 [TBL] [Abstract][Full Text] [Related]
26. FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma. Huynh H; Prawira A; Le TBU; Vu TC; Hao HX; Huang A; Wang Y; Porta DG Exp Mol Med; 2020 Nov; 52(11):1857-1868. PubMed ID: 33235319 [TBL] [Abstract][Full Text] [Related]
27. Up-regulation of fibroblast growth factor 19 and its receptor associates with progression from fatty liver to hepatocellular carcinoma. Li Y; Zhang W; Doughtie A; Cui G; Li X; Pandit H; Yang Y; Li S; Martin R Oncotarget; 2016 Aug; 7(32):52329-52339. PubMed ID: 27447573 [TBL] [Abstract][Full Text] [Related]
28. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043 [TBL] [Abstract][Full Text] [Related]
29. Discovery of novel FGFR4 inhibitors through a build-up fragment strategy. Kim J; Im CG; Oh K; Lee JM; Al-Rubaye F; Min KH J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2343350. PubMed ID: 38655602 [TBL] [Abstract][Full Text] [Related]
30. Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma. Lin ZZ; Hsu C; Jeng YM; Hu FC; Pan HW; Wu YM; Hsu HC; Hu MC; Cheng AL Liver Int; 2019 Sep; 39(9):1682-1691. PubMed ID: 30698907 [TBL] [Abstract][Full Text] [Related]
31. Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling. Pai R; Dunlap D; Qing J; Mohtashemi I; Hotzel K; French DM Cancer Res; 2008 Jul; 68(13):5086-95. PubMed ID: 18593907 [TBL] [Abstract][Full Text] [Related]
32. Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19. Zhou M; Wang X; Phung V; Lindhout DA; Mondal K; Hsu JY; Yang H; Humphrey M; Ding X; Arora T; Learned RM; DePaoli AM; Tian H; Ling L Cancer Res; 2014 Jun; 74(12):3306-16. PubMed ID: 24728076 [TBL] [Abstract][Full Text] [Related]
33. Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma. Poh W; Wong W; Ong H; Aung MO; Lim SG; Chua BT; Ho HK Mol Cancer; 2012 Mar; 11():14. PubMed ID: 22439738 [TBL] [Abstract][Full Text] [Related]
34. FGF19 Protects Hepatocellular Carcinoma Cells against Endoplasmic Reticulum Stress via Activation of FGFR4-GSK3β-Nrf2 Signaling. Teng Y; Zhao H; Gao L; Zhang W; Shull AY; Shay C Cancer Res; 2017 Nov; 77(22):6215-6225. PubMed ID: 28951455 [TBL] [Abstract][Full Text] [Related]
35. First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. Kim RD; Sarker D; Meyer T; Yau T; Macarulla T; Park JW; Choo SP; Hollebecque A; Sung MW; Lim HY; Mazzaferro V; Trojan J; Zhu AX; Yoon JH; Sharma S; Lin ZZ; Chan SL; Faivre S; Feun LG; Yen CJ; Dufour JF; Palmer DH; Llovet JM; Manoogian M; Tugnait M; Stransky N; Hagel M; Kohl NE; Lengauer C; Sherwin CA; Schmidt-Kittler O; Hoeflich KP; Shi H; Wolf BB; Kang YK Cancer Discov; 2019 Dec; 9(12):1696-1707. PubMed ID: 31575541 [TBL] [Abstract][Full Text] [Related]
36. Combination of FGFR4 inhibitor Blu9931 and 5-fluorouracil effects on the biological characteristics of colorectal cancer cells. Jiang D; Li J; Li J; Wang M; Han C; Wang X; Zhao C; Ye Y Int J Oncol; 2017 Nov; 51(5):1611-1620. PubMed ID: 29048661 [TBL] [Abstract][Full Text] [Related]
37. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Desnoyers LR; Pai R; Ferrando RE; Hötzel K; Le T; Ross J; Carano R; D'Souza A; Qing J; Mohtashemi I; Ashkenazi A; French DM Oncogene; 2008 Jan; 27(1):85-97. PubMed ID: 17599042 [TBL] [Abstract][Full Text] [Related]
38. FGFR4 provides the conduit to facilitate FGF19 signaling in breast cancer progression. Zhao X; Xu F; Dominguez NP; Xiong Y; Xiong Z; Peng H; Shay C; Teng Y Mol Carcinog; 2018 Nov; 57(11):1616-1625. PubMed ID: 30074276 [TBL] [Abstract][Full Text] [Related]
39. Fibroblast Growth Factor 15/19 in Hepatocarcinogenesis. Alvarez-Sola G; Uriarte I; Latasa MU; Urtasun R; Bárcena-Varela M; Elizalde M; Jiménez M; Rodriguez-Ortigosa CM; Corrales FJ; Fernández-Barrena MG; Berasain C; Avila MA Dig Dis; 2017; 35(3):158-165. PubMed ID: 28249259 [TBL] [Abstract][Full Text] [Related]
40. Molecular subclasses of hepatocellular carcinoma predict sensitivity to fibroblast growth factor receptor inhibition. Schmidt B; Wei L; DePeralta DK; Hoshida Y; Tan PS; Sun X; Sventek JP; Lanuti M; Tanabe KK; Fuchs BC Int J Cancer; 2016 Mar; 138(6):1494-505. PubMed ID: 26481559 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]